KYTX (Kyverna Therapeutics) ROE % Adjusted to Book Value: -27.82% (As of Mar. 2026)


KYTX Kyverna Therapeutics Inc KYTX
12 GF Score
Price $8.77
! 1 Warning Sign
View Full Analysis

What is Kyverna Therapeutics ROE % Adjusted to Book Value?

Kyverna Therapeutics KYTX +4.03% 12 ROE % Adjusted to Book Value is -27.82% as of Mar. 2026. GuruFocus rates KYTX with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Kyverna Therapeutics's ROE % for the quarter that ended in Mar. 2026 was -74.28%. Kyverna Therapeutics's PB Ratio for the quarter that ended in Mar. 2026 was 2.67. Kyverna Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 was -27.82%.

Kyverna Therapeutics ROE % Adjusted to Book Value Related Terms

Kyverna Therapeutics ROE % Adjusted to Book Value Historical Data

* Premium members only.

The historical data trend for Kyverna Therapeutics's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kyverna Therapeutics ROE % Adjusted to Book Value Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
ROE % Adjusted to Book Value
0.00 0.00 0.00 -309.16 -26.50

Kyverna Therapeutics Quarterly Data
Dec21 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -196.70 -114.49 -50.58 -32.26 -27.82

KYTX vs ZURA, CBIO, ARVN: ROE % Adjusted to Book Value Comparison

For the Biotechnology subindustry, Kyverna Therapeutics's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Kyverna Therapeutics ROE % Adjusted to Book Value vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kyverna Therapeutics's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Kyverna Therapeutics's ROE % Adjusted to Book Value falls into.


KYTX
12GF Score
Kyverna Therapeutics Inc KYTX
ROE % Adjusted to Book Value is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Kyverna Therapeutics ROE % Adjusted to Book Value Calculation

Kyverna Therapeutics's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2025 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-64.67% / 2.44
=-26.50%

Kyverna Therapeutics's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2026 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-74.28% / 2.67
=-27.82%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROE % Adjusted to Book Value of -27.82% mean?
Kyverna Therapeutics (KYTX) has a ROE % Adjusted to Book Value of -27.82% as of Mar. 2026. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Kyverna Therapeutics and its competitors.
Is Kyverna Therapeutics' ROE % Adjusted to Book Value too high?
Kyverna Therapeutics' current ROE % Adjusted to Book Value is -27.82%. Overall, Kyverna Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kyverna Therapeutics' ROE % Adjusted to Book Value compare to ZURA and CBIO?
Kyverna Therapeutics' ROE % Adjusted to Book Value of -27.82% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Biotechnology company?
A good ROE % Adjusted to Book Value depends on the Biotechnology industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Kyverna Therapeutics and its competitors. Kyverna Therapeutics's current ROE % Adjusted to Book Value is -27.82%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kyverna Therapeutics stock overvalued right now?
Kyverna Therapeutics (KYTX) has a current ROE % Adjusted to Book Value of -27.82%. The current ROE % Adjusted to Book Value is -27.82%. Kyverna Therapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Kyverna Therapeutics (KYTX), the current ROE % Adjusted to Book Value is -27.82% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kyverna Therapeutics Business Description

Address 5980 Horton Street, Suite 550, Emeryville, CA, USA, 94608
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product, KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
12GF Score

Get the complete analysis for KYTX

ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$8.77
Price